Stool tests catch the majority of colorectal cancers, but their accuracy depends heavily on which test you use, what stage the cancer is at, and what threshold your lab applies. The fecal immunochemical test (FIT), the most widely used stool screening test worldwide, detects roughly 80% to 93% of colorectal cancers depending on those variables, while correctly ruling out cancer in about 91% to 94% of people who don’t have it. That sounds reassuring, and for population-level screening it genuinely is. But the numbers get more complicated once you look at early-stage cancers, precancerous polyps, and what happens when real-world conditions come into play.
The Three Main Stool Tests
Three stool-based tests are currently recommended for colorectal cancer screening in the United States and many other countries. The oldest is the guaiac-based fecal occult blood test (gFOBT), which uses a chemical reaction to detect blood in stool. When a stool sample is applied to guaiac-impregnated paper and a developer solution is added, the presence of hemoglobin triggers a color change to blue.1BMJ. Faecal occult blood testing: a review of its use and common misutilisation The problem is that this reaction isn’t specific to human blood. Foods with natural peroxidase activity, like raw broccoli or red meat, and certain medications can trigger the same reaction, leading to false positives or requiring dietary restrictions before testing.
FIT replaced gFOBT as the standard in most screening programs because it uses antibodies that specifically target human hemoglobin. You don’t need to change your diet before collecting the sample. FIT also has lower false-positive and false-negative rates than gFOBT.2PubMed Central. The effectiveness of FOBT vs. FIT: A meta-analysis on colorectal cancer screening test One caveat with FIT: proton-pump inhibitors (common heartburn drugs) can increase the positivity rate without a corresponding increase in actual disease, essentially producing more false alarms.1BMJ. Faecal occult blood testing: a review of its use and common misutilisation
The third option is the multi-target stool DNA test (mt-sDNA), sold in the U.S. as Cologuard. It combines a FIT hemoglobin measurement with analysis of DNA methylation and mutation markers shed by abnormal cells into the stool.3PubMed Central. Next-generation Multi-target Stool DNA Panel Accurately Detects Colorectal Cancer and Advanced Precancerous Lesions The mt-sDNA test has higher sensitivity for cancer than FIT alone, but it costs substantially more and is recommended at longer intervals (every one to three years instead of annually for FIT).4JAMA. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
How Sensitivity Changes by Cancer Stage
A headline sensitivity figure for FIT is misleading if you don’t know that the test performs very differently at different stages of disease. A study tracking FIT performance across tumor stages found that the test caught only about half of the earliest-stage tumors (T1, which are confined to the innermost layer of the colon wall), while sensitivity climbed to 93% for T3 tumors that had grown through the muscle layer. Broken out by clinical stage, FIT detected about 68% of stage I cancers compared with 92% of stage II and 89% of stage IV cancers.5Clinical Gastroenterology and Hepatology. Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location
This makes biological sense. Larger, more advanced tumors tend to bleed more and more often, so a test that detects blood is naturally better at finding them. The practical implication is that FIT is excellent at catching the cancers most likely to be immediately dangerous, but it misses roughly a third of the earliest cancers on any single round of testing. The strategy that compensates for this is annual retesting: a cancer that was too small to bleed detectably this year may bleed enough to trigger a positive result next year, while still at a treatable stage.
The Threshold Matters More Than You Think
FIT is a quantitative test. It measures the concentration of hemoglobin in your stool and compares that number to a cutoff threshold. Where your screening program sets that cutoff dramatically changes the test’s accuracy profile. A systematic review and meta-analysis found that at thresholds of 10 micrograms per gram of feces or lower, FIT sensitivity for colorectal cancer was about 80%, with specificity around 91%. Raising the cutoff above 10 and up to 20 micrograms per gram dropped sensitivity to about 69% but improved specificity to roughly 94%.6PubMed Central. Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis
In populations at increased risk for colorectal cancer, the numbers look even better. A meta-analysis of FIT in higher-risk patients found pooled sensitivity of 93% and specificity of 91% for cancer detection, with subgroup analyses suggesting cutoffs between 15 and 25 micrograms per gram offered the best balance of both.7JAMA Internal Medicine. Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer: A Meta-analysis
This is not a free lunch. Lowering the threshold catches more cancers but also flags more people who don’t have cancer, leading to more unnecessary colonoscopies. Raising it misses more cancers but reduces the burden on endoscopy resources. A joint guideline from UK gastroenterology societies acknowledged this tension directly: the threshold chosen in practice reflects a balance between tolerance for missed cancers and the diagnostic capacity available to investigate positive results.8PubMed Central. Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) Different countries have landed in different places. This is one reason you might see widely varying sensitivity figures quoted in different contexts: they’re often measuring the same test at different thresholds.
Where Stool Tests Fall Short on Precancerous Polyps
If stool tests are reasonably good at catching established cancers, they are considerably less reliable at finding precancerous polyps, the growths most screening programs hope to catch before they turn malignant. A meta-analysis of FIT for advanced adenomas, the polyps most likely to progress to cancer, found pooled sensitivity of just 36% and specificity of 89%.9BJS Open. Diagnostic accuracy of the faecal immunochemical test and volatile organic compound analysis in detecting colorectal polyps: meta-analysis In a surveillance population study of patients with prior polyps, FIT detected no cancers (because there were none in that cohort) and had limited accuracy for advanced precancerous lesions, consistent with other studies reporting roughly 50% to 80% sensitivity for cancer but lower figures for pre-malignant findings.10PubMed Central. Accuracy of Fecal Immunochemical Tests for Detecting Advanced Colorectal Neoplasia at Surveillance Colonoscopy
This is the central limitation of all blood-based stool tests: they can only find lesions that bleed into the stool. Precancerous polyps bleed intermittently and often minimally. Colonoscopy, by contrast, finds polyps visually regardless of whether they are bleeding on the day of the exam. For average-risk people who are comfortable with annual testing and prompt follow-up colonoscopy after a positive result, FIT works well as a screening strategy. But if you have a personal or family history that puts you at higher risk for polyps, a direct-visualization approach like colonoscopy may be more appropriate. That decision is worth discussing with a doctor rather than defaulting to whichever test seems easiest.
What a Positive Result Actually Means
Getting a positive stool test does not mean you have cancer. A study using data from the New Hampshire Colonoscopy Registry examined what colonoscopies actually found after positive stool tests. The false discovery rate, meaning the percentage of positive tests that did not find a clinically significant lesion on follow-up colonoscopy, ranged from about 33% to 48% for FIT and about 32% to 72% for mt-sDNA, depending on how broadly “clinically significant” was defined.11Preventive Medicine Reports. What do ‘false-positive’ stool tests really mean? Data from the New Hampshire colonoscopy registry
The wide ranges reflect a genuinely thorny question in the field: what counts as a “true positive”? If a positive FIT leads to a colonoscopy that finds a small, low-risk polyp and the gastroenterologist recommends coming back in five years instead of ten, is that a true positive or a false alarm? It depends on who you ask. When the definition includes only frank cancer and high-risk adenomas, the false-positive rate looks high. When it includes any finding that changes the recommended surveillance interval, the rate drops considerably.
A real-world study of Cologuard follow-up found that only about 38% of positive results corresponded to significant lesions on colonoscopy, and just 44% of patients with positive results completed the follow-up colonoscopy at all.12PubMed Central. From Detection to Delay: Real-World Gaps in Post-Cologuard® Colonoscopy Adherence That second number is arguably the bigger problem. A positive stool test that never gets followed up with colonoscopy is worse than useless: it has cost money, caused anxiety, and still left a potential cancer undiagnosed.
Interval Cancers and What FIT Misses
An interval cancer is one that appears between screening rounds, after a negative test. These represent the test’s blind spots, and they are not trivial. In a large Belgian screening program, about 13% of all colorectal cancers diagnosed during the study period were interval cancers, detected after a negative FIT. These interval cancers were more likely to be right-sided (in the part of the colon farthest from the rectum), advanced at diagnosis, and poorly differentiated, meaning more aggressive in character.13PubMed Central. Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the “interval cancer” perspective Interval cancers were also more common in women and in the oldest age group screened (70 to 74).
A Spanish study of nearly half a million participants with negative FIT results quantified the risk: the two-year cumulative incidence of interval cancer ranged from about 10 to 14 per 10,000 people, depending on whether a lower or higher cutoff threshold was used.14PubMed. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age A larger study corroborated that most post-FIT interval cancers occurred in the distal colon, and that lower colonoscopist skill levels (measured by adenoma detection rate) increased the risk of post-colonoscopy interval cancers as well.15JAMA Network Open. Interval Colorectal Cancers in a Fecal Immunochemical Test–Based Screening Program
Right-sided colon cancers are a known weak spot for FIT because blood from lesions in the ascending colon has to travel the entire length of the large intestine before reaching stool. Hemoglobin degrades along the way, reducing the concentration that the test eventually measures. This is a hard limitation of the technology, and one reason researchers are interested in supplementing hemoglobin detection with other stool biomarkers.
FIT Versus Colonoscopy for Reducing Deaths
Colonoscopy is often described as the “gold standard,” but a randomized trial directly comparing the two strategies produced results that might surprise you. The COLONPREV trial, a large pragmatic trial in Spain, found that a FIT-based screening program was statistically non-inferior to colonoscopy-based screening for colorectal cancer mortality over ten years. Colorectal cancer death rates were 0.24% in the FIT group and 0.22% in the colonoscopy group, a difference that was not statistically meaningful.16PubMed. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial
A key reason for this is participation. More people actually complete a stool test when invited than show up for a colonoscopy. If a perfect test only gets used by half the target population, its real-world impact shrinks. A population-based case-control study reinforced this dynamic, finding that people who had undergone FIT screening had a lower likelihood of being diagnosed with colorectal cancer. The protective effect grew stronger with repeated testing: people who had completed five or more FIT rounds over ten years had roughly half the cancer risk of unscreened individuals.17PubMed Central. Colon Colonoscopy Versus Fecal Immunochemical Test for Reducing Colorectal Cancer Risk: A Population-Based Case–Control Study The lesson is that stool testing is a strategy, not a single event. Its power comes from repetition.
Practical Factors That Can Shift Your Results
FIT accuracy isn’t only about biology. Environmental conditions during sample transport can matter. A study in the Netherlands found that higher ambient temperatures were associated with lower FIT sensitivity, especially at higher cutoff thresholds. Hemoglobin in the sample degrades in heat. The time the sample spent in transit (a median of six days) did not independently affect accuracy, but temperature during those days did.18PubMed Central. Accuracy of a fecal immunochemical test according to outside temperature and travel time If you collect a FIT sample during a summer heat wave and it sits in a hot mailbox for a few days, the hemoglobin may partially break down before the lab analyzes it, potentially turning a true positive into a false negative.
Medications also play a role. The older gFOBT is particularly vulnerable to interference from aspirin, NSAIDs, and dietary peroxidases, to the point that controlling for all of these in a hospital setting was described in one commentary as making the test “even more useless” in that context.19JAMA Internal Medicine. Medication Effects on Fecal Occult Blood Testing—Reply FIT is much less affected by diet and most medications, but proton-pump inhibitors remain a source of excess false positives.
Age and sex also influence test performance. The meta-analysis examining FIT threshold effects found that both variables modified accuracy, which is part of why some programs have explored using sex- and age-specific cutoff values rather than a single universal threshold.6PubMed Central. Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis FIT performance in younger adults appears strong based on recent data from England, where adults under 50 who were tested with FIT showed sensitivity above 92% for colorectal cancer at the standard threshold, though positive predictive values were much lower in younger patients simply because cancer is rarer in that age group.20PubMed Central. The diagnostic accuracy of the faecal immunochemical test for the detection of early-onset colorectal cancer: an age-stratified analysis in South West England
The Follow-Up Gap
The biggest real-world threat to stool-test accuracy isn’t the test itself, it’s what happens after a positive result. A review of multiple California public hospital systems found that only 42% of patients with an abnormal FIT received a follow-up colonoscopy. Older age, lack of insurance, and Medicaid coverage were all associated with lower follow-up rates.21PubMed Central. Extent of Follow-Up on Abnormal Cancer Screening in Multiple California Public Hospital Systems: A Retrospective Review Racial disparities compound the problem: follow-up colonoscopy rates are significantly lower for Black Americans than for White Americans.22Cancer Epidemiology, Biomarkers & Prevention. Abstract A138: Impact of racial disparities in follow-up colonoscopy for abnormal stool-screening test results on colorectal cancer incidence and mortality: A simulation modeling analysis
A simulation study modeled how adherence patterns affect outcomes and found that under realistic conditions, mt-sDNA outperformed FIT largely because patients were more likely to complete the mt-sDNA test (71% vs. 43% screening adherence in the published data used). But when the model assumed perfect adherence to both the screening test and the follow-up colonoscopy, annual FIT actually produced greater reductions in cancer incidence and mortality than mt-sDNA.23PubMed Central. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes The implication is clear: the best test is the one you actually complete, including the colonoscopy afterward if needed.
How the Tests Compare on Cost
Accuracy and cost intersect in screening programs because the money spent on false-positive colonoscopies is money not available for other care. A cost-effectiveness analysis published in JAMA Network Open found that annual FIT was the only screening strategy that produced net cost savings compared with no screening, while also yielding the most quality-adjusted life years gained. Triennial mt-sDNA tests were less cost-effective, and triennial blood-based tests (a newer category) were the least cost-effective of the strategies modeled.24JAMA Network Open. Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics A separate analysis found that among non-colonoscopy alternatives, CT colonography every five years was the most cost-effective, with annual mt-sDNA screening having a much higher cost per quality-adjusted life year gained.25PubMed Central. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests
FIT’s cost advantage is straightforward: the test itself is cheap, it requires no dietary preparation, and it produces fewer false positives than mt-sDNA, meaning fewer unnecessary colonoscopies. The trade-off is that you need to do it every year and that it catches fewer advanced polyps per round. For health systems trying to screen millions of people, that trade-off tends to favor FIT.
Emerging Stool Biomarkers
Researchers are working to address FIT’s blind spots, particularly for right-sided cancers and precancerous polyps, by adding non-hemoglobin biomarkers to stool testing. One of the most studied additions is Fusobacterium nucleatum (Fn), a gut bacterium found at higher levels in colorectal tumors. A meta-analysis of Fn as a standalone diagnostic marker found pooled sensitivity of about 70% and specificity of 79% for colorectal cancer.26PubMed Central. Diagnostic value of fecal Fusobacterium nucleatum in colorectal cancer Those numbers aren’t good enough to replace FIT, but the combination is where things get interesting.
Adding quantitative Fn measurement to FIT significantly improved sensitivity for colorectal cancer from about 73% to 92% in one study, without a major loss in specificity. The combined test produced an area under the curve of 0.95, substantially better than FIT alone.27PubMed Central. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia More recent work has demonstrated that Fn can be detected directly from leftover FIT samples using sensitive PCR techniques, meaning the combination could potentially be run on the same sample you already collected for your regular screening without any extra effort on your part.28PubMed. Enhancing Colorectal Cancer Screening with Droplet Digital PCR Analysis of Fusobacterium nucleatum in Fecal Immunochemical Test Samples
Stool microRNA panels are another avenue under investigation, with early studies identifying over 140 microRNAs with altered expression levels in stool samples from cancer patients compared with healthy controls.29Cancer Research. Abstract LB-330: Stool and plasma miRNA profiles by next-generation sequencing: a study on subjects with colorectal cancer and precancerous lesions None of these additions have made it into routine clinical practice yet, but the direction of travel is toward multi-layered stool tests that combine hemoglobin detection with microbial and molecular markers to close the gaps that FIT on its own cannot.
Cumulative False Positives Over a Lifetime of Screening
One underappreciated aspect of repeated annual testing is the accumulation of false-positive risk over time. A Markov modeling study calculated that for a test with 98% specificity used every two years from age 50 to 74, the cumulative false-positive rate at age 74 was substantial. Decreasing specificity from 98% to 95% more than doubled the cumulative false-positive burden, and dropping to 92% tripled it.30PubMed Central. The cumulative false-positive rate in colorectal cancer screening: a Markov analysis Screening more frequently (annually instead of biennially) also increases the cumulative risk of at least one false alarm over a screening lifetime. This doesn’t mean annual FIT is a bad idea; it catches more cancers. But it means you should expect that at some point over two decades of testing, you may get a positive result that leads to a clean colonoscopy. That is a normal and anticipated part of the screening process, not a failure of the test.